Savara (NASDAQ:SVRA) Trading Up 2.6%

Shares of Savara Inc (NASDAQ:SVRA - Get Free Report) were up 2.6% during trading on Wednesday . The stock traded as high as $4.82 and last traded at $4.79. Approximately 371,286 shares were traded during mid-day trading, a decline of 54% from the average daily volume of 807,856 shares. The stock had previously closed at $4.67.

Analysts Set New Price Targets

Several analysts have commented on SVRA shares. JMP Securities started coverage on shares of Savara in a research report on Thursday, February 15th. They issued an "outperform" rating and a $8.00 target price for the company. Piper Sandler boosted their target price on shares of Savara from $7.00 to $16.00 and gave the stock an "overweight" rating in a research report on Monday, March 4th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus price target of $8.20.

Savara Stock Up 2.6 %

The firm has a market cap of $661.74 million, a price-to-earnings ratio of -14.52 and a beta of 0.77. The company has a debt-to-equity ratio of 0.19, a quick ratio of 15.66 and a current ratio of 15.66. The business's 50-day moving average is $4.96 and its 200-day moving average is $4.30.

Savara (NASDAQ:SVRA - Get Free Report) last issued its earnings results on Thursday, March 7th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.02. On average, equities analysts predict that Savara Inc will post -0.38 EPS for the current year.

Hedge Funds Weigh In On Savara

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SVRA. Jennison Associates LLC raised its stake in Savara by 128.0% in the fourth quarter. Jennison Associates LLC now owns 8,815,358 shares of the company's stock valued at $41,432,000 after purchasing an additional 4,948,596 shares in the last quarter. Adage Capital Partners GP L.L.C. raised its stake in Savara by 30.9% during the third quarter. Adage Capital Partners GP L.L.C. now owns 7,938,551 shares of the company's stock worth $30,008,000 after acquiring an additional 1,874,000 shares in the last quarter. Vanguard Group Inc. raised its stake in Savara by 2.6% during the fourth quarter. Vanguard Group Inc. now owns 5,914,947 shares of the company's stock worth $27,800,000 after acquiring an additional 150,346 shares in the last quarter. BlackRock Inc. raised its stake in Savara by 369.0% during the second quarter. BlackRock Inc. now owns 4,898,576 shares of the company's stock worth $15,651,000 after acquiring an additional 3,854,198 shares in the last quarter. Finally, Vivo Capital LLC raised its stake in Savara by 9.1% during the fourth quarter. Vivo Capital LLC now owns 2,088,323 shares of the company's stock worth $9,815,000 after acquiring an additional 174,974 shares in the last quarter. 87.93% of the stock is owned by institutional investors.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.